Literature DB >> 29483359

FHR5 Binds to Laminins, Uses Separate C3b and Surface-Binding Sites, and Activates Complement on Malondialdehyde-Acetaldehyde Surfaces.

Ramona B Rudnick1, Qian Chen1, Emma Diletta Stea1, Andrea Hartmann1, Nikolina Papac-Milicevic2,3, Fermin Person4, Michael Wiesener5, Christoph J Binder2,3, Thorsten Wiech4, Christine Skerka1, Peter F Zipfel6,7.   

Abstract

Factor H related-protein 5 (CFHR5) is a surface-acting complement activator and variations in the CFHR5 gene are linked to CFHR glomerulonephritis. In this study, we show that FHR5 binds to laminin-521, the major constituent of the glomerular basement membrane, and to mesangial laminin-211. Furthermore, we identify malondialdehyde-acetaldehyde (MAA) epitopes, which are exposed on the surface of human necrotic cells (Homo sapiens), as new FHR5 ligands. Using a set of novel deletion fragments, we show that FHR5 binds to laminin-521, MAA epitopes, heparin, and human necrotic cells (HUVECs) via the middle region [short consensus repeats (SCRs) 5-7]. In contrast, surface-bound FHR5 contacts C3b via the C-terminal region (SCRs8-9). Thus, FHR5 uses separate domains for C3b binding and cell surface interaction. MAA epitopes serve as a complement-activating surface by recruiting FHR5. The complement activator FHR5 and the complement inhibitor factor H both bind to oxidation-specific MAA epitopes and FHR5 competes with factor H for binding. The C3 glomerulopathy-associated FHR21-2-FHR5 hybrid protein is more potent in MAA epitope binding and activation compared with wild-type FHR5. The implications of these results for pathology of CFHR glomerulonephritis are discussed. In conclusion, we identify laminins and oxidation-specific MAA epitopes as novel FHR5 ligands and show that the surface-binding site of FHR5 (SCRs5-7) is separated from the C3b binding site (SCRs8-9). Furthermore, FHR5 competes with factor H for binding to MAA epitopes and activates complement on these modified structures.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29483359     DOI: 10.4049/jimmunol.1701641

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

Review 2.  Self-Damage Caused by Dysregulation of the Complement Alternative Pathway: Relevance of the Factor H Protein Family.

Authors:  Pilar Sánchez-Corral; Richard B Pouw; Margarita López-Trascasa; Mihály Józsi
Journal:  Front Immunol       Date:  2018-07-12       Impact factor: 7.561

3.  Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies.

Authors:  Sarah Irmscher; Silke R Brix; Svante L H Zipfel; Luke D Halder; Sibel Mutlutürk; Sonia Wulf; Evaldas Girdauskas; Hermann Reichenspurner; Rolf A K Stahl; Berit Jungnickel; Thorsten Wiech; Peter F Zipfel; Christine Skerka
Journal:  Nat Commun       Date:  2019-07-04       Impact factor: 14.919

4.  Glomerular Complement Factor H-Related Protein 5 (FHR5) Is Highly Prevalent in C3 Glomerulopathy and Associated With Renal Impairment.

Authors:  Nicholas R Medjeral-Thomas; Hilary Moffitt; Hannah J Lomax-Browne; Nicholas Constantinou; Tom Cairns; H Terence Cook; Matthew C Pickering
Journal:  Kidney Int Rep       Date:  2019-06-19

5.  A genome-wide association study identifies key modulators of complement factor H binding to malondialdehyde-epitopes.

Authors:  Lejla Alic; Nikolina Papac-Milicevic; Darina Czamara; Ramona B Rudnick; Maria Ozsvar-Kozma; Andrea Hartmann; Michael Gurbisz; Gregor Hoermann; Stefanie Haslinger-Hutter; Peter F Zipfel; Christine Skerka; Elisabeth B Binder; Christoph J Binder
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-22       Impact factor: 11.205

6.  Complement Factor H-Related 3 Enhanced Inflammation and Complement Activation in Human RPE Cells.

Authors:  Nicole Schäfer; Anas Rasras; Delia M Ormenisan; Sabine Amslinger; Volker Enzmann; Herbert Jägle; Diana Pauly
Journal:  Front Immunol       Date:  2021-11-08       Impact factor: 7.561

Review 7.  Complement catalyzing glomerular diseases.

Authors:  Peter F Zipfel; Thorsten Wiech; Hermann-Josef Gröne; Christine Skerka
Journal:  Cell Tissue Res       Date:  2021-10-06       Impact factor: 4.051

8.  Interaction of the Factor H Family Proteins FHR-1 and FHR-5 With DNA and Dead Cells: Implications for the Regulation of Complement Activation and Opsonization.

Authors:  Éva Kárpáti; Alexandra Papp; Andrea E Schneider; Dávid Hajnal; Marcell Cserhalmi; Ádám I Csincsi; Barbara Uzonyi; Mihály Józsi
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

9.  The failure of two major formaldehyde catabolism enzymes (ADH5 and ALDH2) leads to partial synthetic lethality in C57BL/6 mice.

Authors:  Jun Nakamura; Darcy W Holley; Toshihiro Kawamoto; Scott J Bultman
Journal:  Genes Environ       Date:  2020-06-03

10.  FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy.

Authors:  Nóra Garam; Marcell Cserhalmi; Zoltán Prohászka; Ágnes Szilágyi; Nóra Veszeli; Edina Szabó; Barbara Uzonyi; Attila Iliás; Christof Aigner; Alice Schmidt; Martina Gaggl; Gere Sunder-Plassmann; Dóra Bajcsi; Jürgen Brunner; Alexandra Dumfarth; Daniel Cejka; Stefan Flaschberger; Hana Flögelova; Ágnes Haris; Ágnes Hartmann; Andreas Heilos; Thomas Mueller; Krisztina Rusai; Klaus Arbeiter; Johannes Hofer; Dániel Jakab; Mária Sinkó; Erika Szigeti; Csaba Bereczki; Viktor Janko; Kata Kelen; György S Reusz; Attila J Szabó; Nóra Klenk; Krisztina Kóbor; Nika Kojc; Maarten Knechtelsdorfer; Mario Laganovic; Adrian Catalin Lungu; Anamarija Meglic; Rina Rus; Tanja Kersnik Levart; Ernesta Macioniene; Marius Miglinas; Anna Pawłowska; Tomasz Stompór; Ludmila Podracka; Michael Rudnicki; Gert Mayer; Romana Rysava; Jana Reiterova; Marijan Saraga; Tomáš Seeman; Jakub Zieg; Eva Sládková; Natasa Stajic; Tamás Szabó; Andrei Capitanescu; Simona Stancu; Miroslav Tisljar; Kresimir Galesic; András Tislér; Inga Vainumäe; Martin Windpessl; Tomas Zaoral; Galia Zlatanova; Mihály Józsi; Dorottya Csuka
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.